Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial
14 February 2020 - 12:00AM
Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage
biotechnology company focused on developing and commercializing
novel cancer therapeutics that reactivate mutant p53 tumor
suppressor protein, today announced the appointment of Gregory S.
Wessels to the newly created position of Vice President,
Commercial. An experienced biotech executive, Mr. Wessels brings to
Aprea nearly 23 years of experience in sales, marketing and
commercialization strategy, most recently having served as
Executive Director - US Marketing for Lymphoma and Acute Myeloid
Leukemia at Bristol-Myers Squibb.
“We are excited to welcome Greg to the Aprea team as we continue
our progress towards key upcoming milestones,” said Christian S.
Schade, President and Chief Executive Officer of Aprea
Therapeutics. “Greg’s leadership and broad commercialization
experiences in launching new therapies are essential to help drive
Aprea’s future plans to bring our novel, p53-targeted oncology
therapies to patients in need.”
Mr. Wessels added, “Aprea has made significant progress in the
development of a breakthrough therapy for patients with limited
therapeutic options. I look forward to joining the team and
building a commercial organization focused on bringing important
new therapies to patients with cancer.”
Prior to joining Aprea from BMS, Mr. Wessels held global and
regional oncology marketing positions of increasing responsibility
over more than 11 years at Celgene Corporation. Prior to joining
Celgene he spent 11 years with Sanofi US in sales, marketing and
business planning roles. Mr. Wessels received a BS in Biochemistry
from the University of Notre Dame and an MBA from the Kellogg
School of Management at Northwestern University.
About Aprea Therapeutics
Aprea Therapeutics Inc., (NASDAQ: APRE) is a biopharmaceutical
company headquartered in Boston, Massachusetts with research
facilities in Stockholm, Sweden, focused on developing and
commercializing novel cancer therapeutics that reactivate the
mutant tumor suppressor protein p53. The Company’s lead product
candidate is APR-246, a small molecule in clinical development for
hematologic malignancies, including myelodysplastic syndromes (MDS)
and acute myeloid leukemia (AML). For more information, please
visit the company website at www.aprea.com.
The Company may use, and intends to use, its investor relations
website at http://ir.aprea.com/ as a means of disclosing material
nonpublic information and for complying with its disclosure
obligations under Regulation FD.
About p53 and APR-246
The p53 tumor suppressor gene is the most frequently mutated
gene in human cancer, occurring in approximately 50% of all human
tumors. These mutations are often associated with resistance to
anti-cancer drugs and poor overall survival, representing a major
unmet medical need in the treatment of cancer.
APR-246 is a small molecule that has demonstrated reactivation
of mutant and inactivated p53 protein – by restoring wild-type p53
conformation and function – and thereby induce programmed cell
death in human cancer cells. Pre-clinical anti-tumor activity has
been observed with APR-246 in a wide variety of solid and
hematological cancers, including MDS, AML, and ovarian cancer,
among others. Additionally, strong synergy has been seen with both
traditional anti-cancer agents, such as chemotherapy, as well as
newer mechanism-based anti-cancer drugs and immuno-oncology
checkpoint inhibitors. In addition to pre-clinical testing, a Phase
1/2 clinical program with APR-246 has been completed, demonstrating
a favorable safety profile and both biological and confirmed
clinical responses in hematological malignancies and solid tumors
with mutations in the TP53 gene.
A pivotal Phase 3 clinical trial of APR-246 and azacitidine for
frontline treatment of TP53 mutant MDS is ongoing. APR-246 has
received Breakthrough Therapy, Orphan Drug and Fast Track
designations from the FDA for MDS, and Orphan Drug designation from
the EMA for MDS, AML and ovarian cancer.
Forward-Looking Statements
Certain information contained in this press release includes
“forward-looking statements”, within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, related to our
clinical trials and regulatory submissions. We may, in some cases
use terms such as “predicts,” “believes,” “potential,” “continue,”
“anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “likely,” “will,” “should” or other words that
convey uncertainty of the future events or outcomes to identify
these forward-looking statements. Our forward-looking statements
are based on current beliefs and expectations of our management
team that involve risks, potential changes in circumstances,
assumptions, and uncertainties. Any or all of the forward-looking
statements may turn out to be wrong or be affected by inaccurate
assumptions we might make or by known or unknown risks and
uncertainties. These forward-looking statements are subject to
risks and uncertainties including risks related to the success and
timing of our clinical trials or other studies and the other risks
set forth in our filings with the U.S. Securities and Exchange
Commission, including our Quarterly Report on Form 10-Q. For all
these reasons, actual results and developments could be materially
different from those expressed in or implied by our forward-looking
statements. You are cautioned not to place undue reliance on these
forward-looking statements, which are made only as of the date of
this press release. We undertake no obligation to publicly update
such forward-looking statements to reflect subsequent events or
circumstances.
Corporate Contacts:
Scott M. CoianteSr. Vice President and Chief Financial
Officer617-463-9385
Gregory A. KorbelVice President of Business
Development617-463-9385
Source: Aprea Therapeutics, Inc.
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jul 2023 to Jul 2024